Precigen, Inc. (PGEN)Healthcare | Biotechnology | Germantown, United States | NasdaqGS
6.95 USD
-0.24
(-3.338%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 7.00 +0.05 (0.719%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:03 a.m. EDT
The immediate outlook is mixed but leans cautiously positive due to a sharp technical rebound. The stock has rallied nearly 25% over the last two weeks, breaking above key moving averages, which suggests momentum traders are stepping in. However, this rally is occurring against a backdrop of severe long-term distress; the company has lost over 85% of its value over the last nine years and is burning cash with no dividend to support shareholders. While the recent FDA approval news and strong revenue growth provide a necessary catalyst for the short term, the balance sheet remains fragile with debt significantly exceeding cash reserves. The options market reflects this tension, with heavy betting on a crash alongside bets on a continuation of the rally. For now, the technical bounce offers a limited-entry opportunity, but the fundamental reality remains precarious. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.098431 |
| MSTL | 0.122773 |
| AutoARIMA | 0.125297 |
| AutoETS | 0.125298 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 4.06 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.177 |
| Excess Kurtosis | -1.36 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 225.686 |
| Revenue per Share | 0.25 |
| Market Cap | 2,477,751,296 |
| Forward P/E | -31.59 |
| Beta | 1.01 |
| Profit Margins | -183.98% |
| Website | https://precigen.com |
As of Aug. 22, 2026, 3:03 a.m. EDT: Speculators are positioning aggressively for downside protection with massive open interest in deep out-of-the-money puts (strikes 3.0 and 4.0) for the October expiration, indicating a fear of a significant drop. Conversely, call activity is concentrated in the money and slightly out-of-the-money strikes (5.0, 7.0, 8.0), suggesting a belief that the recent recovery will continue, though the heavy put volume creates a distinct asymmetry favoring sellers.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.51050425 |
| Address1 | 20,374 Seneca Meadows Parkway |
| All Time High | 68.83053 |
| All Time Low | 0.65 |
| Ask | 7.97 |
| Ask Size | 1 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 6,055,370 |
| Average Daily Volume3 Month | 5,461,827 |
| Average Volume | 5,461,827 |
| Average Volume10Days | 6,055,370 |
| Beta | 1.009 |
| Bid | 5.95 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 0.122 |
| City | Germantown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.95 |
| Current Ratio | 4.578 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 7.19 |
| Day Low | 6.92 |
| Debt To Equity | 225.686 |
| Display Name | Precigen |
| Earnings Call Timestamp End | 1,785,875,400 |
| Earnings Call Timestamp Start | 1,785,875,400 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -35,359,000 |
| Ebitda Margins | -0.41251 |
| Enterprise To Ebitda | -72.074 |
| Enterprise To Revenue | 29.731 |
| Enterprise Value | 2,548,482,048 |
| Eps Forward | -0.22 |
| Eps Trailing Twelve Months | -1.03 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.9894 |
| Fifty Day Average Change | 0.9605999 |
| Fifty Day Average Change Percent | 0.16038333 |
| Fifty Two Week Change Percent | 51.050423 |
| Fifty Two Week High | 7.72 |
| Fifty Two Week High Change | -0.77 |
| Fifty Two Week High Change Percent | -0.09974093 |
| Fifty Two Week Low | 2.99 |
| Fifty Two Week Low Change | 3.9599998 |
| Fifty Two Week Low Change Percent | 1.3244146 |
| Fifty Two Week Range | 2.99 - 7.72 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,375,968,600,000 |
| Float Shares | 194,470,425 |
| Forward Eps | -0.22 |
| Forward P E | -31.590908 |
| Free Cashflow | -100,097,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 160 |
| Fullday Change | -0.24 |
| Fullday Change Percent | -3.33797 |
| Fullday Price | 7.0 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.53006 |
| Gross Profits | 45,435,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12674 |
| Held Percent Institutions | 0.72488 |
| Implied Shares Outstanding | 356,510,980 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. |
| Long Name | Precigen, Inc. |
| Market | us_market |
| Market Cap | 2,477,751,296 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_22365961 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -336,704,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,570,693,073 |
| Number Of Analyst Opinions | 2 |
| Open | 7.11 |
| Operating Cashflow | -114,165,000 |
| Operating Margins | 0.41184 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 301 556 9900 |
| Post Market Change | 0.05000019 |
| Post Market Change Percent | 0.7194272 |
| Post Market Price | 7.0 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 7.19 |
| Price Hint | 2 |
| Price To Book | 56.967213 |
| Price To Sales Trailing12 Months | 28.906183 |
| Profit Margins | -1.83983 |
| Quick Ratio | 3.756 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.24 |
| Regular Market Change Percent | -3.33797 |
| Regular Market Day High | 7.19 |
| Regular Market Day Low | 6.92 |
| Regular Market Day Range | 6.92 - 7.19 |
| Regular Market Open | 7.11 |
| Regular Market Previous Close | 7.19 |
| Regular Market Price | 6.95 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 2,702,336 |
| Return On Assets | -0.18139 |
| Return On Equity | -8.37075 |
| Revenue Growth | 63.227 |
| Revenue Per Share | 0.25 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 356,510,980 |
| Shares Percent Shares Out | 0.118 |
| Shares Short | 42,240,157 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 41,025,860 |
| Short Name | Precigen, Inc. |
| Short Percent Of Float | 0.2164 |
| Short Ratio | 8.2 |
| Source Interval | 15 |
| State | MD |
| Symbol | PGEN |
| Target High Price | 18.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 14.5 |
| Target Median Price | 14.5 |
| Total Cash | 38,208,000 |
| Total Cash Per Share | 0.107 |
| Total Debt | 98,345,000 |
| Total Revenue | 85,717,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.03 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.56215 |
| Two Hundred Day Average Change | 2.3878498 |
| Two Hundred Day Average Change Percent | 0.5234045 |
| Type Disp | Equity |
| Volume | 2,702,336 |
| Website | https://precigen.com |
| Zip | 20,876 |